Clinical cancer research : an official journal of the American Association for Cancer Research
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, Elizabeth K Lee, Devalingam Mahalingam, Martin Højgaard, Niharika B Mettu, Gregory M Cote, Ruth Plummer, Maria Koehler, Danielle Ulanet, Kezhen Fei, Ian M Silverman, Joseph D Schonhoft, Victoria Rimkunas
Published: 202610.1158/1078-0432.CCR-25-2240
Abstract
PURPOSE: The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor (ATRi), in mediating tumor cell death was assessed in preclinical models, prompting clinical investigation. The…
Preview only. Read the full abstract at the source